Soothing seaweed: Fucoidan extracts found to reduce gut inflammation
05 Nov 2018 --- Maritech fucoidan – a bioactive compound extracted from seaweed – can inhibit the production of key pro-inflammatory biomarkers that are clinically relevant in acute and chronic gut condition, new research has found. Maritech fucoidan ingredients are extracted from wild Undaria pinnatifida and Fucus vesiculosus macroalgae by Australian biotechnology company Marinova. When tested in ex-vivo human blood and compared to controls, results showed that fucoidan inhibited the release of three inflammatory mediators; TNF-α, IL-1β and IL-6. TNF-α and IL-1β are drivers of major inflammatory processes. Prolonged and raised levels are linked to inflammatory bowel disease (IBD), which affects 10 million people worldwide and includes Crohn’s disease and ulcerative colitis. Blocking these chemical messengers can result in a rapid and sustained reduction in disease severity. Maritech fucoidan was found to reduce TNF-α levels by more than 70 percent and IL-1β by more than 54 percent. The pro-inflammatory cytokine IL-6 also plays a central role in uncontrolled intestinal inflammation. It can alter the balance between pro-inflammatory and immunosuppressive immune cells, and has been associated with IBD and colon cancer. In the study, Maritech fucoidan inhibited the production of IL-6 by more than 43 percent. “It’s truly exciting that a naturally-derived marine ingredient has demonstrated such profound anti-inflammatory benefits with great potential to improve gut and digestive health,” says Dr. Helen Fitton, Chief Scientist at Marinova, commenting on the significance of the research. “Fucoidan has long been valued for its ability to address both local and systemic inflammation. This activity is ascribed to its biological role in protecting the seaweed plant from inflammation, caused by UV light and pathogens.” The study is part of Marinova’s gut and digestive health research program. It builds on a series of in vitro and animal models, in which Maritech fucoidan reportedly inhibited key inflammatory enzymes expressed in the gastrointestinal tract and reduced the clinical symptoms and pathology of ulcerative colitis. “Our fucoidan ingredients already feature in a large number of products targeting gut health. In fact, gut health is a key growing indication for Marinova, given the comprehensive research that supports this application,” Claire Smoorenburg, Marketing & Communications Officer at Marinova, tells NutritionInsight. “Following on from these research results, Marinova is embarking on a clinical trial in the human microbiome. This is part of the company’s diverse pipeline of R&D planned in gut and digestive health, in addition to our pillar research areas of immune modulation and integrative oncology,” she adds. To contact our editorial team please email us at editorial@cnsmedia.com
Related ArticlesHealth & Nutrition News Examining DNA derived from GM foods: Scientists probe how it penetrates the body's cells22 Jan 2019 --- Toxicologists, including scientists from the Far Eastern Federal University (FEFU), studying the potential risks of genetically modified (GM) products have published a review on the fate of the DNA derived from GM food and how it can survive during digestion and penetrate into the cells of the body. One of the key findings is that the micro-ribonucleic acid – one of the main molecules in cells of living organisms – of GM foods that were treated with insecticides and antiviral sprays can affect genetic processes in the bodies of those who consume it. Health & Nutrition News “Achieving the purity of wild ginseng”: Botalys taps into expanding adaptogenic market with new launch22 Jan 2019 --- Botalys, a supplier of rare plant extracts, is to launch what it describes as the most bioactive Panax ginseng powder on the market, coined HRG80. The launch is to take place at Vitafoods Europe 2019, held in May in Geneva, and Natural Origins group will be in charge of its Western Europe distribution. Ginseng’s mainly used for its stress-reducing properties, Paul-Evence Coppée, Co-CEO of Botalys, tells NutritionInsight, and the plant is “considered by many to be the king of adaptogens.” Health & Nutrition News Microbiome medicine: “Unlocking” the secrets behind fecal transplant “super donors”22 Jan 2019 --- Fecal transplants could be used to treat intestinal disorders such as inflammatory bowel disease, and perhaps even help prevent Alzheimer's and cancer, if the secrets of the gut-rejuvenating properties of “super donors” could be unlocked, say Australian researchers. The researchers reviewed fecal transplantation trials for clues to the origin of the “super-donor” phenomenon, yet concluded that further research is needed to uncover the role of external factors, such as diet and naturally occurring gut diversity. Health & Nutrition News Sustainable diets? Mixed responses to landmark EAT Lancet dietary overhaul recommendations21 Jan 2019 --- Industry experts and academics have aired mixed responses to last week’s landmark EAT Lancet study, which calls for an overhaul of global everyday diets to safeguard global health and avoid damage to the planet. The significant recommendations include amendments to food production and reductions in food waste. Although many have welcomed the study’s goals and scientific approach, questions have been posed as to the viability of the far stretching policy changes it proposes, as well as the utility of one set of dietary recommendations deemed to be suitable for everyone. Health & Nutrition News Genes affect where our bodies store fat, Swedish study finds21 Jan 2019 --- Whether your body stores fat around the trunk or in other bodily parts is highly influenced by genetic factors and this effect is more predominant in women than in men. This is according to a recent study from Uppsala University, published in Nature Communications, which measured how fat was distributed in nearly 360,000 voluntary participants. More Articles |
